Daré Bioscience (NASDAQ:DARE) Share Price Crosses Above 50-Day Moving Average of $0.45

Daré Bioscience, Inc. (NASDAQ:DARE) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.45 and traded as high as $0.48. Daré Bioscience shares last traded at $0.48, with a volume of 137,000 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Dawson James lowered Daré Bioscience from a “buy” rating to a “neutral” rating in a report on Tuesday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Daré Bioscience in a report on Monday, April 1st.

Daré Bioscience Stock Performance

The stock has a market capitalization of $48.14 million, a price-to-earnings ratio of -1.41 and a beta of 1.16. The business has a fifty day simple moving average of $0.45 and a 200 day simple moving average of $0.40.

Institutional Trading of Daré Bioscience

Several large investors have recently modified their holdings of DARE. Bank of New York Mellon Corp acquired a new stake in shares of Daré Bioscience during the 1st quarter worth $34,000. Citigroup Inc. acquired a new stake in shares of Daré Bioscience during the 1st quarter worth $40,000. Bank of America Corp DE acquired a new stake in shares of Daré Bioscience during the 1st quarter worth $44,000. Morgan Stanley grew its holdings in shares of Daré Bioscience by 283.4% during the 4th quarter. Morgan Stanley now owns 67,646 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 50,000 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Daré Bioscience by 11,198.4% during the 3rd quarter. UBS Group AG now owns 56,492 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 55,992 shares in the last quarter. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.